Innate immunity and inflammation - New frontiers in comparative cardiovascular pathology

Cardiovascular Research

Volumn 73, Issue 1, 2007, Pages 26-36

  Linde, Annika ^a   Mosier, Derek ^a   Blecha, Frank ^a   Melgarejo, Tonatiuh ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial peptides; Innate immunity; Nuclear factor kappa beta; Toll like receptors

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; POLYPEPTIDE ANTIBIOTIC AGENT; STAT PROTEIN; TOLL LIKE RECEPTOR;

HEART DISEASE; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CARDIOVASCULAR DISEASES; CELL NUCLEUS; CYTOKINES; HUMANS; IMMUNITY, NATURAL; MYOCARDIUM; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 33845595623     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.08.009     Document Type: Review

References (101)

1. Janeway Jr. C.A., Travers P., Walport M., and Shlomchik M.J. Immunobiology. 6 edition (2004), Garland Publishing
2. Feuerstein G.Z., Libby P., and Mann D.L. Inflammation-a new frontier in cardiac disease and therapeutics. In: Feuerstein G.Z., Libby P., and Mann D.L. (Eds). Inflammation and cardiac diseases (2003), Birkhauser Verlag, Basel, Switzerland 1-5
3. Ibrahim M.A., Chain B.M., and Katz D.R. The injured cell: the role of the dendritic cell system as a sentinel receptor pathway. Immunol Today 16 (1995) 181-186
4. Rescigno M., Granucci F., and Ricciardi-Castagnoli P. Dendritic cells at the end of the millennium. Immunol Cell Biol 77 (1999) 404-410
5. Goerdt S., Kodelja V., Schmuth M., Orfanos C.E., and Sorg C. The mononuclear phagocyte-dendritic cell dichotomy: myths, facts, and a revised concept. Clin Exp Immunol 105 (1996) 1-9
6. Lo D., Feng L., Li L., Carson M.J., Crowley M., Pauza M., et al. Integrating innate and adaptive immunity in the whole animal. Immunol Rev 169 (1999) 225-239
7. Weyrich A.S., and Zimmerman G.A. Platelets: signaling cells in the immune continuum. Trends Immunol 25 (2004) 489-495
8. Rumbo M., Anderle P., Didierlaurent A., Sierro F., Debard N., Sirard J.C., et al. How the gut links innate and adaptive immunity. Ann NY Acad Sci 1029 (2004) 16-21
9. Fredj S., Bescond J., Louault C., and Potreau D. Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. J Cell Physiol 202 (2005) 891-899
10. Libby P. Inflammation and atherosclerosis. Nature 420 (2003) 868-874
11. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
12. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 95 (2005) 3C-8C
13. Gullestad L., and Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 95 (2005) 17C-23C
14. Janeway Jr. C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symp Quant Biol 54 Pt 1 (1989) 1-13
15. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavell R.A., et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303 (2004) 1522-1526
16. Frantz S., Kelly R.A., and Bourcier T. Toll-like receptors and the cardiovascular system. In: Feuerstein G.Z., Libby P., and Mann D.L. (Eds). Inflammation and cardiac diseases (2003), Birkhauser Verlag, Basel, Switzerland 129-141
17. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 413 (2001) 732-738
18. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 388 (1997) 394-397
19. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., and Nishijima M. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 275 (2000) 2251-2254
20. Cowan D.B., Poutias D.N., Del Nido P.J., and McGowan Jr. F.X. CD14-independent activation of cardiomyocyte signal transduction by bacterial endotoxin. Am J Physiol Heart Circ Physiol 279 (2000) H619-H629
21. Comstock K.L., Krown K.A., Page M.T., Martin D., Ho P., Pedraza M., et al. LPS-induced TNF-alpha release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol Cell Cardiol 30 (1998) 2761-2775
22. Cowan D.B., Noria S., Stamm C., Garcia L.M., Poutias D.N., Del Nido P.J., et al. Lipopolysaccharide internalization activates endotoxin-dependent signal transduction in cardiomyocytes. Circ Res 88 (2001) 491-498
23. Kawai T., Adachi O., Ogawa T., Takeda K., and Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11 (1999) 115-122
24. Knuefermann P., Nemoto S., Baumgarten G., Misra A., Sivasubramanian N., Carabello B.A., et al. Cardiac inflammation and innate immunity in septic shock: is there a role for toll-like receptors?. Chest 121 (2002) 1329-1336
25. Underhill D.M., and Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14 (2002) 103-110
26. Sen R., and Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46 (1986) 705-716
27. Jones W.K., Brown M., Ren X., He S., and McGuinness M. NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling?. Cardiovasc Toxicol 3 (2003) 229-254
28. Dawn B., Xuan Y.T., Marian M., Flaherty M.P., Murphree S.S., Smith T.L., et al. Cardiac-specific abrogation of NF-kappa B activation in mice by transdominant expression of a mutant I kappa B alpha. J Mol Cell Cardiol 33 (2001) 161-173
29. Birbach A., Gold P., Binder B.R., Hofer E., de M.R., and Schmid J.A. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem 277 (2002) 10842-10851
30. Suyang H., Phillips R., Douglas I., and Ghosh S. Role of unphosphorylated, newly synthesized I kappa B beta in persistent activation of NF-kappa B. Mol Cell Biol 16 (1996) 5444-5449
31. Haudek S.B., Spencer E., Bryant D.D., White D.J., Maass D., Horton J.W., et al. Overexpression of cardiac I-kappaBalpha prevents endotoxin-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 280 (2001) H962-H968
32. Senftleben U., Cao Y., Xiao G., Greten F.R., Krahn G., Bonizzi G., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293 (2001) 1495-1499
33. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Gold H.K., and Finn A.V. Inflammation and coronary artery disease. In: Feuerstein G.Z., Libby P., and Mann D.L. (Eds). Inflammation and cardiac diseases (2003), Birkhauser Verlag, Basel, Switzerland 21-53
34. Opitz B., Forster S., Hocke A.C., Maass M., Schmeck B., Hippenstiel S., et al. Nod1-mediated endothelial cell activation by Chlamydophila pneumoniae. Circ Res 96 (2005) 319-326
35. Rodriguez-Martinez S., Cancino-Diaz M.E., Jimenez-Zamudio L., Garcia-Latorre E., and Cancino-Diaz J.C. TLRs and NODs mRNA expression pattern in healthy mouse eye. Br J Ophthalmol 89 (2005) 904-910
36. Sasaki H., Fukuda S., Otani H., Zhu L., Yamaura G., Engelman R.M., et al. Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction. J Mol Cell Cardiol 34 (2002) 335-348
37. Yin L., Hubbard A.K., and Giardina C. NF-kappa B regulates transcription of the mouse telomerase catalytic subunit. J Biol Chem 275 (2002) 36671-36675
38. Bril A., and Feuerstein G.Z. The role of IL-6 and related cytokines in myocardial remodeling and inflammation-implication for cardiac hypertrophy and heart failure. In: Feuerstein G.Z., Libby P., and Mann D.L. (Eds). Inflammation and cardiac diseases (2003), Birkhauser Verlag, Basel, Switzerland 111-127
39. Stephanou A. Role of STAT-1 and STAT-3 in ischaemia/reperfusion injury. J Cell Mol Med 8 (2004) 519-525
40. Harada M., Qin Y., Takano H., Minamino T., Zou Y., Toko H., et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11 (2005) 305-311
41. Mascareno E., and Siddiqui M.A. The role of Jak/STAT signaling in heart tissue renin-angiotensin system. Mol Cell Biochem 212 (2000) 171-175
42. Wang T.L., Yang Y.H., Chang H., and Hung C.R. Angiotensin II signals mechanical stretch-induced cardiac matrix metalloproteinase expression via JAK-STAT pathway. J Mol Cell Cardiol 37 (2004) 785-794
43. O'shea J.J., Park H., Pesu M., Borie D., and Changelian P. New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr Opin Rheumatol 17 (2005) 305-311
44. Lammerding J., Kamm R.D., and Lee R.T. Mechanotransduction in cardiac myocytes. Ann NY Acad Sci 1015 (2004) 53-70
45. Baines C.P., and Molkentin J.D. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38 (2005) 47-62
46. Aukrust P., Yndestad A., Damas J.K., and Gullestad L. Therapeutic potential of anticytokine therapy in congestive heart failure. Am J Cardiovasc Drugs 4 (2004) 169-177
47. Paulus W.J. Cytokines and heart failure. Heart Fail Monit 1 (2000) 50-56
48. Tang V., Dhirapong A., Yabes A.P., and Weiss R.H. TNF-alpha-mediated apoptosis in vascular smooth muscle cells requires p73. Am J Physiol Cell Physiol 289 (2005) C199-C206
49. Amar J., Fauvel J., Drouet L., Ruidavets J.B., Perret B., Chamontin B., et al. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 24 (2006) 1089-1095
50. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol 274 (1998) R577-R595
51. Zhang M., Xu Y.J., Saini H.K., Turan B., Liu P.P., and Dhalla N.S. TNF-alpha as a potential mediator of cardiac dysfunction due to intracellular Ca2+-overload. Biochem Biophys Res Commun 327 (2005) 57-63
52. Libera L.D., and Vescovo G. Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation?. Curr Opin Clin Nutr Metab Care 7 (2004) 435-441
53. Cain B.S., Meldrum D.R., Dinarello C.A., Meng X., Joo K.S., Banerjee A., et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 27 (1999) 1309-1318
54. Friedrichs G.S., Swillo R.E., Jow B., Bridal T., Numann R., Warner L.M., et al. Sphingosine modulates myocyte electrophysiology, induces negative inotropy, and decreases survival after myocardial ischemia. J Cardiovasc Pharmacol 39 (2002) 18-28
55. Lecour S., Rochette L., and Opie L. Free radicals trigger TNF alpha-induced cardioprotection. Cardiovasc Res 65 (2005) 239-243
56. Tanhehco E.J., and Sabbah H.N. The role of IL-6 in experimental and clinical heart failure. In: Feuerstein G.Z., Libby P., and Mann D.L. (Eds). Inflammation and cardiac diseases (2003), Birkhauser Verlag, Basel, Switzerland 143-151
57. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
58. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
59. Anker S.D., and Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86 (2002) 123-130
60. Bozkurt B., Torre-Amione G., Warren M.S., Whitmore J., Soran O.Z., Feldman A.M., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103 (2001) 1044-1047
61. Cush J.J. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 22 (2004) S141-S147
62. Gullestad L., Kjekshus J., Damas J.K., Ueland T., Yndestad A., and Aukrust P. Agents targeting inflammation in heart failure. Expert Opin Investig Drugs 14 (2005) 557-566
63. Fiordaliso F., Chimenti S., Staszewsky L., Bai A., Carlo E., Cuccovillo I., et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 102 (2005) 2046-2051
64. Cao C.M., Xia Q., Tu J., Chen M., Wu S., and Wong T.M. Cardioprotection of interleukin-2 is mediated via kappa-opioid receptors. J Pharmacol Exp Ther 309 (2004) 560-567
65. Rafiee P., Shi Y., Su J., Pritchard Jr. K.A., Tweddell J.S., and Baker J.E. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 100 (2005) 187-197
66. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., and Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18 (2004) 1031-1033
67. Sasayama S. Immunomodulation in heart failure: experimental models. In: Feuerstein G.Z., Libby P., and Mann D.L. (Eds). Inflammation and cardiac diseases (2003), Birkhauser Verlag, Basel, Switzerland 203-219
68. Kamysz W., Okroj M., and Lukasiak J. Novel properties of antimicrobial peptides. Acta Biochim Pol 50 (2003) 461-469
69. Hancock R.E., and Diamond G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8 (2000) 402-410
70. Ganz T. Defensins and host defense. Science 286 (1999) 420-421
71. Ganz T., and Lehrer R.I. Antimicrobial peptides of vertebrates. Curr Opin Immunol 10 (1998) 41-44
72. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
73. Page R.A., and Malik A.N. Elevated levels of beta defensin-1 mRNA in diabetic kidneys of GK rats. Biochem Biophys Res Commun 310 (2003) 513-521
74. Schutte B.C., and McCray Jr. P.B. [beta]-defensins in lung host defense. Annu Rev Physiol 64 (2002) 709-748
75. Krisanaprakornkit S., Kimball J.R., and Dale B.A. Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-kappaB transcription factor family. J Immunol 168 (2002) 316-324
76. Jia H.P., Schutte B.C., Schudy A., Linzmeier R., Guthmiller J.M., Johnson G.K., et al. Discovery of new human beta-defensins using a genomics-based approach. Gene 263 (2001) 211-218
77. Zhang G., Wu H., Shi J., Ganz T., Ross C.R., and Blecha F. Molecular cloning and tissue expression of porcine beta-defensin-1. FEBS Lett 424 (1998) 37-40
78. Davis E.G., Sang Y., and Blecha F. Equine beta-defensin-1: full-length cDNA sequence and tissue expression. Vet Immunol Immunopathol 99 (2004) 127-132
79. Morrison G., Kilanowski F., Davidson D., and Dorin J. Characterization of the mouse beta defensin 1, Defb1, mutant mouse model. Infect Immun 70 (2002) 3053-3060
80. Knuefermann P., Vallejo J., and Mann D.L. The role of innate immune responses in the heart in health and disease. Trends Cardiovasc Med 14 (2004) 1-7
81. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 12 (1994) 991-1045
82. Wang S., Kotamraju S., Konorev E., Kalivendi S., Joseph J., and Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 367 (2002) 729-740
83. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., and Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 98 (2001) 6668-6673
84. Higuchi Y., Otsu K., Nishida K., Hirotani S., Nakayama H., Yamaguchi O., et al. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 34 (2002) 233-240
85. Sivasubramanian N., Coker M.L., Kurrelmeyer K.M., MacLellan W.R., DeMayo F.J., Spinale F.G., et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104 (2001) 826-831
86. Kubota T., Miyagishima M., Frye C.S., Alber S.M., Bounoutas G.S., Kadokami T., et al. Overexpression of tumor necrosis factor- alpha activates both anti- and pro-apoptotic pathways in the myocardium. J Mol Cell Cardiol 33 (2001) 1331-1344
87. McGowan B.S., Ciccimaro E.F., Chan T.O., and Feldman A.M. The balance between pro-apoptotic and anti-apoptotic pathways in the failing myocardium. Cardiovasc Toxicol 3 (2003) 191-206
88. Kajstura J., Cheng W., Reiss K., Clark W.A., Sonnenblick E.H., Krajewski S., et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 74 (1996) 86-107
89. Edfeldt K., Swedenborg J., Hansson G.K., and Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105 (2002) 1158-1161
90. Vink A., Schoneveld A.H., van der Meer J.J., van Middelaar B.J., Sluijter J.P., Smeets M.B., et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106 (2002) 1985-1990
91. Shishido T., Nozaki N., Yamaguchi S., Shibata Y., Nitobe J., Miyamoto T., et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108 (2003) 2905-2910
92. Olbrich H.G. Epidemiology-etiology of dilated cardiomyopathy. Z Kardiol 90 Suppl 1 (2001) 2-9
93. Maisch B., Richter A., Sandmoller A., Portig I., and Pankuweit S. Inflammatory dilated cardiomyopathy (DCMI). Herz 30 (2005) 535-544
94. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and Classification of cardiomyopathies. Circulation 93 (1996) 841-842
95. Breitschwerdt E.B., Blann K.R., Stebbins M.E., Munana K.R., Davidson M.G., Jackson H.A., et al. Clinicopathological abnormalities and treatment response in 24 dogs seroreactive to Bartonella vinsonii (berkhoffii) antigens. J Am Anim Hosp Assoc 40 (2004) 92-101
96. Rothenburger M., Trosch F., Markewitz A., Berendes E., Schmid C., Scheld H., et al. Leukocyte activation and phagocytotic activity in cardiac surgery and infection. Cardiovasc Surg 10 (2002) 470-475
97. Methe H., Zimmer E., Grimm C., Nabauer M., and Koglin J. Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 78 (2004) 1324-1331
98. Stocker C.F., Shekerdemian L.S., Visvanathan K., Skinner N., Brizard C.P., Carlin J.B., et al. Cardiopulmonary bypass elicits a prominent innate immune response in children with congenital heart disease. J Thorac Cardiovasc Surg 127 (2004) 1523-1525
99. Dybdahl B., Wahba A., Lien E., Flo T.H., Waage A., Qureshi N., et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 105 (2002) 685-690
100. Feuerstein G.Z., Libby P., and Mann D.L. Summary: immune and inflammatory modulators as potential therapeutic targets for cardiac diseases. In: Feuerstein G.Z., Libby P., and Mann D.L. (Eds). Inflammation and cardiac diseases (2003), Birkhauser Verlag, Basel, Switzerland 407-409
101. Shumway S.D., Maki M., and Miyamoto S. The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain. J Biol Chem 274 (1999) 30874-30881